GT Biopharma, Inc. short interest in 2022
In 2022, GT Biopharma, Inc.'s disclosed short interest ran from 3.18% of shares outstanding on 14 Jan 2022 to 1.00% on 30 Dec 2022, a change of -2.18 percentage points. The year's high was 5.16% on 31 May 2022 and its low 1.00% on 30 Dec 2022, averaging 3.02% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.85 days on 14 Apr 2022. Full history: GT Biopharma, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 3.18% (14 Jan 2022)
- End of year
- 1.00% (30 Dec 2022)
- Change
- -2.18 pp
- High
- 5.16% (31 May 2022)
- Low
- 1.00% (30 Dec 2022)
- Average
- 3.02%
- Highest days to cover
- 13.85 (14 Apr 2022)
- SEC filings marked
- 4
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 3.18% | 5.05 | |
| 31 Jan 2022 | 3.73% | 5.42 | |
| 15 Feb 2022 | 4.21% | 8.66 | |
| 28 Feb 2022 | 4.88% | 6.33 | |
| 15 Mar 2022 | 4.95% | 12.99 | |
| 31 Mar 2022 | 4.31% | 11.12 | 10-K filed |
| 14 Apr 2022 | 4.67% | 13.85 | |
| 29 Apr 2022 | 4.84% | 11.48 | |
| 13 May 2022 | 4.95% | 9.37 | |
| 31 May 2022 | 5.16% | 7.47 | 10-Q filed |
| 15 Jun 2022 | 4.77% | 8.28 | |
| 30 Jun 2022 | 2.51% | 1.99 | |
| 15 Jul 2022 | 2.13% | 4.69 | |
| 29 Jul 2022 | 2.11% | 5.71 | |
| 15 Aug 2022 | 1.87% | 7.12 | 10-Q filed |
| 31 Aug 2022 | 2.16% | 5.87 | |
| 15 Sep 2022 | 2.30% | 4.68 | |
| 30 Sep 2022 | 1.86% | 5.41 | |
| 14 Oct 2022 | 1.68% | 12.23 | |
| 31 Oct 2022 | 1.34% | 6.77 | 10-Q filed |
| 15 Nov 2022 | 1.49% | 11.50 | |
| 30 Nov 2022 | 1.25% | 7.77 | |
| 15 Dec 2022 | 1.16% | 4.17 | |
| 30 Dec 2022 | 1.00% | 4.90 |
See also: GT Biopharma, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.